HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.

AuthorsR V Moerman, S Arends, P M Meiners, E Brouwer, F K L Spijkervet, F G M Kroese, A Vissink, H Bootsma
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 73 Issue 2 Pg. 472-4 (Feb 2014) ISSN: 1468-2060 [Electronic] England
PMID23940214 (Publication Type: Letter, Randomized Controlled Trial)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab
Topics
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Double-Blind Method
  • Humans
  • Immunologic Factors (therapeutic use)
  • Rituximab
  • Severity of Illness Index
  • Sjogren's Syndrome (drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: